Compass vs atai vs GH Research — A Head-to-Head on the Three Psychedelic Names
Compass vs atai vs GH Research — A Head-to-Head on the Three Psychedelic Names
TL;DR Compass Pathways is the most clinically advanced single-drug bet; atai is a diversified portfolio play with five compounds and Peter Thiel backing; GH Research is a session-time differentiation bet on a 30-minute compound. None have revenue yet, so this is calculated speculation, not investment.
Same category, three completely different bets
All three names jumped together the day after the April 18 executive order, but that surface symmetry hides three very different risk-reward profiles.
| Attribute | Compass (CMPS) | atai Life Sciences (ATAI) | GH Research (GHRS) |
|---|---|---|---|
| Bet type | Single-drug concentration | Portfolio diversification | Technology differentiation |
| Core asset | COMP360 (synthetic psilocybin) | 5 compounds in clinical | 5-MeO-DMT single compound |
| Clinical stage | Phase 3 completed | Phase 1-2 across portfolio | Phase 2 |
| Session duration | 6-8 hours | Compound-dependent | ~30 minutes |
| From all-time high | ~-83% | ~-95% | ~-70% |
| Revenue today | None | None | None |
The shared trait is the one that matters: none have meaningful revenue. Traditional valuation does not work here. This is catalyst-driven speculation.
Compass Pathways (CMPS) — The furthest along
Compass is the most clinically advanced name in the category. Their lead asset, COMP360, is a synthetic form of the active compound in magic mushrooms (psilocybin), targeting treatment-resistant depression — the same patient pool J&J's Spravato is already serving.
What stands out:
- Phase 3 trial completed, with 26-week durability data — a first for any psychedelic
- Single-dose protocol, with effects measurable within 24 hours
- Expected FDA decision window: late 2026 to early 2027
- Market cap roughly in the $1B range
If approved, Compass becomes the first company in history to bring a classic psychedelic to market via the FDA pathway. The stock traded as high as ~$60 in its 2021 IPO run, and has spent years grinding sideways and down. From what I've found, that is the cleanest "nothing happened for years, now starting to inflect" setup — historically the highest probability shape for innovation names.
atai Life Sciences (ATAI) — The diversified portfolio bet
atai is a different kind of company. Instead of betting on one molecule, it is structured like a venture portfolio with five compounds in clinical development.
Key points:
- Merged with Beckley Psytech in December 2025, broadening the pipeline
- Holds a position in Compass — indirect Compass exposure baked in
- Licenses Compass's compound in certain territories
- Peter Thiel backed
- Several pipeline candidates target a take-home format with no clinical setting required — potentially decisive for commercial scaling
The diversification means one or two failures do not kill the thesis. The trade-off is that no single approval moves the stock as violently as a Compass approval would.
GH Research (GHRS) — The session-time bet
GH Research's edge is not the drug itself, it is the clock.
Their lead compound, 5-MeO-DMT, has a far shorter duration of action than Compass's psilocybin. A Compass session lasts 6-8 hours. A GH Research session, if it works, lasts about 30 minutes.
From a clinic operator's perspective, this changes the business model completely. Same room, same staff, more patients per day. Commercial adoption can compound much faster.
The downside is concentration risk in a different form — one compound, one mechanism, no portfolio backstop if it fails. The mirror image of atai.
How I'd think about selection
In my view this is not a pick-one game. It is a category bet.
The full position sizing logic is covered in the framework piece, but the headline rule:
- Sized at 1-3% of portfolio, total category exposure
- Distributed across the three names, or concentrated in the most advanced (Compass)
- If a 10x prints, that 1-3% becomes 10-30% — partial profit taking becomes mandatory
Failed FDA approval, dilutive capital raises, and political-environment shifts hit all three names through the same channel. That correlation is exactly why a category-level allocation makes more sense than trying to pick the single winner.
More in this Category
Coherent Wins — A Six-Round Scorecard for Five AI Infrastructure Stocks
Coherent Wins — A Six-Round Scorecard for Five AI Infrastructure Stocks
I scored Coherent (COHR), CoreWeave (CRWV), Nebius (NBIS), Iren (IREN), and Applied Digital (APLD) across six rounds. Coherent took it with 10 points, driven by the only debt-to-equity ratio under 32%.
We're Still in the First Two Innings — Where the AI Infra Buildout Actually Sits
We're Still in the First Two Innings — Where the AI Infra Buildout Actually Sits
Micron nearly doubled from ~$430 to $818 in 30 days while everyone was calling the top. With Big Tech committing $700B to AI infrastructure, this game is in the first two innings.
Five Rules for Treating AI Infrastructure Stocks as Tactical, Not Core
Five Rules for Treating AI Infrastructure Stocks as Tactical, Not Core
Debt-to-equity across the five AI infrastructure plays spans 31% (Coherent) to 387% (CoreWeave). Here are five rules I use to treat them as tactical trades, not core holds.
Next Posts
Cuba's 300 Drones Targeting US Soil — Why Counter-Drone Defense Is the Next Big Theme
Cuba's 300 Drones Targeting US Soil — Why Counter-Drone Defense Is the Next Big Theme
Cuba has stockpiled 300+ Russian and Iranian attack drones in striking range of US infrastructure, with the CIA director personally on the ground. With 11 of 12 counter-drone defense stocks down 30–40% this year, Washington is on the verge of opening the checkbook.
Counter-Drone Defense Stocks in Three Tiers — From Axon to Kratos to Red Cat
Counter-Drone Defense Stocks in Three Tiers — From Axon to Kratos to Red Cat
The most common mistake in the counter-drone theme is ignoring position size and volatility. I sort the names into conservative Tier 1 (XAR, LHX, LMT), aggressive Tier 2 (Kratos, Elbit), and speculative Tier 3 (Red Cat) — with entry conditions for each.
The Three Mistakes That Bleed Retail Investors in Defense Stocks — Plus the Leveraged ETF Trap
The Three Mistakes That Bleed Retail Investors in Defense Stocks — Plus the Leveraged ETF Trap
Retail investors lose in defense for three reasons: chasing headlines, the path-decay trap in leveraged ETFs, and ignoring valuation. Same theme, same timing — the difference between +70% and -20% comes from these three mistakes.
Previous Posts
PayPal's Triple Scenario: How $6B in Buybacks at 6x Free Cash Flow Creates an Asymmetric Bet
PayPal's Triple Scenario: How $6B in Buybacks at 6x Free Cash Flow Creates an Asymmetric Bet
PayPal trades at roughly 6x free cash flow while processing $440B per quarter and sitting 80% off its highs. Here's the buyback math that doubles per-share cash flow in four years without any business improvement.
I Bought Intel at $17 While Everyone Called Me Stupid: What Contrarian Investing Actually Means
I Bought Intel at $17 While Everyone Called Me Stupid: What Contrarian Investing Actually Means
Intel is up roughly 6x in a year, and now everyone says they saw it coming. At $17, the messages I got said the opposite. Here is what the Intel trade actually taught me, and why I think the same pattern is setting up in PayPal.
Getting Paid to Buy Stocks You Already Want: Cash-Secured Puts on PayPal
Getting Paid to Buy Stocks You Already Want: Cash-Secured Puts on PayPal
If you already believe PayPal is cheap, cash-secured puts become a real tool. Here is the structure that lets you buy a $45 stock at $43 while collecting $0.80 per share, and where it goes wrong.